Newsletter | July 22, 2026

07.22.26 -- RNA Platforms: What Transfers And What Breaks

SPONSOR

RNA Leaders USA is the go-to event for advancing RNA therapeutics. Connect with leading experts, explore new ideas, and gain practical insights into the latest RNA developments. Whether you're driving innovation or looking to stay ahead, this event is not to be missed. Join the conversation shaping the future of RNA!

FEATURED EDITORIAL

RNA Platforms: What Transfers And What Breaks

A practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.

The Strategic Shift(s) In gRNA CMC

In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year. 

The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics

Long non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.

RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology

RNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.

INDUSTRY INSIGHTS

Why Transparent Pricing Is Essential For Long-Term R&D Partners

Opaque pricing slows decisions and erodes trust. Transparency clarifies cost drivers, improves budgeting, enables confident sourcing, and strengthens long-term R&D partnerships.

Transitioning Smoothly From Preclinical Designs To cGMP Synthesis

Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

The Future Of CGT: Phase-Appropriate Plasmid DNA Manufacturing

Successful advanced therapy development relies on tailored manufacturing. Matching plasmid quality to your specific clinical phase reduces overall costs and accelerates project timelines.

Why Risk Analysis And Lane Qualification Matter

Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.

Establishing Analytical Methods For mRNA-Based Therapies

Reliable assays are vital for patient safety. Review the technical parameters for sequence identification and LNP lipid composition that support compliant mRNA drug development.

High-Throughput Lipid Separation For LNP Formulations

Lipid nanoparticles (LNPs) carry immense potential as delivery systems. Learn about the development of isocratic and gradient methods for high-throughput separation of lipids used in LNP formulations.

Engineered Enzymes Powering The Future Of mRNA Therapeutics

Optimizing RNA polymerase selection significantly improves mRNA yield and purity while reducing dsRNA. Discover how advanced enzyme engineering enhances manufacturing efficiency and safety.

SOLUTIONS

Fit-For-Purpose And GMP Grade mRNA Reagents

Oligonucleotide Synthesizer Overview

Move Beyond LAL